Evidence map›Paper›PMID 28323898›Full record

ArticlePloS one2017

Perfluorocarbon reduces cell damage from blast injury by inhibiting signal paths of NF-κB, MAPK and Bcl-2/Bax signaling pathway in A549 cells.

Zhaorui Zhang, Zhixin Liang, Huaidong Li, Chunsun Li, Zhen Yang, Yanqin Li, Danyang She, Lu Cao, Wenjie Wang, Changlin Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Establishment and evaluation of anFrontiers in public health · 2022
    Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zhaorui ZhangDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Zhixin LiangDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Huaidong LiDepartment of Respiratory Disease, The 88th Hospital of Chinese PLA, Tai'an City, Shandong Province, People's Republic of China.
Chunsun LiDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Zhen YangDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Yanqin LiDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Danyang SheDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Lu CaoDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Wenjie WangDepartment of State Key Laboratory of Explosion Science and Technology, The Beijing University of Technology, Beijing City, People's Republic of China.
Changlin LiuDepartment of State Key Laboratory of Explosion Science and Technology, The Beijing University of Technology, Beijing City, People's Republic of China.
Liangan ChenDepartment of Respiration, Chinese PLA General Hospital, Beijing City, People's Republic of China.
Chinese PLA General Hospital · CNBeijing University of Technology · CN82th Hospital of Pla · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveBlast lung injury is a common type of blast injury and has very high mortality. Therefore, research to identify medical therapies for blast injury is important. Perfluorocarbon (PFC) is used to improve gas exchange in diseased lungs and has anti-inflammatory functions in vitro and in vivo. The aim of this study was to determine whether PFC reduces damage to A549 cells caused by blast injury and to elucidate its possible mechanisms of action. STUDY DESIGN AND

methodsA549 alveolar epithelial cells exposed to blast waves were treated with and without PFC. Morphological changes and apoptosis of A549 cells were recorded. PCR and enzyme-linked immunosorbent assay (ELISA) were used to measure the mRNA or protein levels of IL-1β, IL-6 and TNF-α. Malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity levels were detected. Western blot was used to quantify the expression of NF-κB, Bax, Bcl-2, cleaved caspase-3 and MAPK cell signaling proteins.

resultsA549 cells exposed to blast wave shrank, with less cell-cell contact. The morphological change of A549 cells exposed to blast waves were alleviated by PFC. PFC significantly inhibited the apoptosis of A549 cells exposed to blast waves. IL-1β, IL-6 and TNF-α cytokine and mRNA expression levels were significantly inhibited by PFC. PFC significantly increased MDA levels and decreased SOD activity levels. Further studies indicated that NF-κB, Bax, caspase-3, phospho-p38, phosphor-ERK and phosphor-JNK proteins were also suppressed by PFC. The quantity of Bcl-2 protein was increased by PFC.

conclusionOur research showed that PFC reduced A549 cell damage caused by blast injury. The potential mechanism may be associated with the following signaling pathways: 1) the signaling pathways of NF-κB and MAPK, which inhibit inflammation and reactive oxygen species (ROS); and 2) the signaling pathways of Bcl-2/Bax and caspase-3, which inhibit apoptosis.

Indexed as

A549 CellsAcute Lung InjuryApoptosisbcl-2-Associated X ProteinBlast InjuriesCaspase 3Cell ShapeFluorocarbonsHumansInterleukin-1betaInterleukin-6MAP Kinase Signaling SystemModels, BiologicalNF-kappa BOxidative StressProto-Oncogene Proteins c-bcl-2BAX protein, humanbcl-2-Associated X ProteinCASP3 protein, humanCaspase 3FluorocarbonsIL6 protein, humanInterleukin-1betaInterleukin-6NF-kappa BProto-Oncogene Proteins c-bcl-2RNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID28323898
PMCPMC5360309
OpenAlexW2600153378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.